A New Expert Consensus Publication Provides Practical Guidance on the Use of Omega-3 Fatty Acids in Parenteral Nutrition

PR82900

BAD HOMBURG, Germany, Feb. 17, 2020 /PRNewswire=KYODO JBN/--

Fresenius Kabi, a global leader in clinical nutrition, announces that the

Journal of Parenteral and Enteral Nutrition (JPEN) has recently published

"Lipids in Parenteral Nutrition: Translating Guidelines into Clinical

Practice".[1] The publication represents the largest set of expert consensus

statements to provide guidance on the use of fish oil-containing lipid

emulsions in clinical practice.   

An international panel of leading experts in clinical nutrition, lipid

metabolism, and pharmacology developed a set of 43 consensus recommendations.

The recommendations aim to help healthcare professionals to navigate issues

around prescription, administration, safety, and monitoring of lipids - from

short- to long-term parenteral nutrition, from pediatric to adult patients,

from home to hospital care.

Fish oil-containing parenteral nutrition has been shown to have a variety of

beneficial effects on key biological functions, including modulation of the

immune and inflammatory response. A growing body of evidence suggests that

these properties improve clinical outcomes, e.g. infection rates, sepsis rate,

length of ICU and hospital stay.[2]

Current guidelines of international clinical societies recommend the use of

fish oil-containing lipid emulsions in parenteral nutrition.[3-5] Regarding

specific nutrients, only parenteral lipid emulsions with EPA + DHA* are

recommended by the European Society for Clinical Nutrition and Metabolism

(ESPEN) guideline on clinical nutrition in the intensive care unit.[4]

To read the summary of consensus statements along with the review of current

evidence on the clinical benefits of omega-3 fatty acids in parenteral

nutrition across the healthcare continuum, visit

https://onlinelibrary.wiley.com/toc/19412444/2020/44/S1.

Register now for the free 2-part educational series offered by the American

Society for Parenteral and Enteral Nutrition (ASPEN) specifically on this

topic: "Expert Consensus on Omega-3 Fatty Acids in Parenteral Nutrition:  Focus

on Critical Care and Major Surgery" on April 22, 2020, and "Expert Consensus on

Omega-3 Fatty Acids in Parenteral Nutrition:  Continuum of Care - From Hospital

to Home Care" on July 9, 2020. Visit the ASPEN Clinical Nutrition Webinar

Series at http://www.nutritioncare.org/webinars/.

* EPA=eicosapentaenoic acid; DHA=docosahexanoic acid

References

1. Martindale R, Berlana D, Boullata J, et al. Lipids in Parenteral Nutrition:

Translating Guidelines into Clinical Practice. JPEN J Parenter Enteral Nutr.

2020;44(suppl S1):S1-S84.

2. Pradelli L, Mayer K, Klek S et al. omega 3 Fatty-Acid Enriched Parenteral

Nutrition in Hospitalized Patients: Systematic Review With Meta-Analysis and

Trial Sequential Analysis. JPEN J Parenter Enteral Nutr. 2020;44(1):44-57.

3. McClave SA, Taylor BE, Martindale RG et al. Guidelines for the Provision and

Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient:

Society of Critical Care Medicine (SCCM) and American Society for Parenteral

and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr.

2016;40(2):159 - 211.

4. Singer P, Blaser AR, Berger MM et al. ESPEN guideline on clinical nutrition

in the intensive care unit. Clin Nutr. 2019;38(1):48 - 79. 5. Lapillonne A,

Fidler Mis N, Goulet O et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric

parenteral nutrition: Lipids. Clin Nutr. 2018;37(6 Pt B):2324-36.

About Fresenius Kabi

Fresenius Kabi is a global healthcare company that specializes in lifesaving

medicines and technologies for infusion, transfusion and clinical nutrition.

The company's products and services are used to help care for critically and

chronically ill patients. Fresenius Kabi's product portfolio comprises a

comprehensive range of I.V. generic drugs, infusion therapies and clinical

nutrition products as well as the devices for administering these products. In

the field of biosimilars, we focus on autoimmune diseases and oncology. In

2019, the first biosimilar product by Fresenius Kabi was launched. Within

transfusion medicine and cell therapies, Fresenius Kabi offers products for

collection and processing of blood and cell components.

With its corporate philosophy of "caring for life", the company is committed to

putting essential medicines and technologies in the hands of people who help

patients and finding the best answers to the challenges they face.

For more information, please visit: fresenius-kabi.com.

For press inquiries, please contact:   

Nina Espiritu    

Edelman GmbH   

Barmbeker Str 4, 22303 Hamburg, Germany    

T: +49-(0)69-401254-345    

nina.espiritu@edelman.com

SOURCE: Fresenius Kabi Deutschland GmbH